* Menveo protects against a cause of meningitis
* Novartis seeking approval in infants and toddlers
* Menveo already approved for people 2-55 years
ZURICH, June 16 (Reuters) – U.S. authorities have accepted Novartis’s application to broaden use of its meningitis vaccine Menveo, the Swiss drugmaker said on Thursday, giving its Vaccines and Diagnostics unit another boost.
Menveo, which protects against strains of the meningococcal disease, a cause of potentially deadly meningitis, is already approved in the United States for people aged between two and 55.
Now the Basel-based drugmaker is also seeking to use it in infants and toddlers from 2 months of age.